Get startedLog in
    Picture of Evaxion A/S logo

    EVAX — Evaxion A/S News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapNeutral
    All News

    Brief: Evaxion Announces Positive Preclinical Data For Cytomegalovirus Vaccine Program EVX-V1

    Picture of Evaxion A/S logoEvaxion A/S
    12/11/2024 13:04
    Nov 12 (Reuters) - Evaxion Biotech A/S  EVAX.O :
    * ANNOUNCES POSITIVE PRECLINICAL DATA FOR CYTOMEGALOVIRUS
(CMV)
VACCINE PROGRAM EVX-V1
    * NEW PRECLINICAL DATA DEMONSTRATES THAT CMV ANTIGENS
IDENTIFIED
WITH EVAXION'S AI-IMMUNOLOGY™ PLATFORM TRIGGER TARGETED IMMUNE
RESPONSES
    * TO DEVELOP MULTI-COMPONENT CMV VACCINE CANDIDATE

Source text:  ID:nGNX57lW92 
Further company coverage:  EVAX.O 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Evaxion A/S

    See all news